Costs of asthma according to the degree of severity

An increase in asthma-related morbidity and mortality has been reported recently, resulting in a substantial increase in the economic impact of this condition. Little information is available relating to the costs of asthma depending on the degree of severity of the disease. Total, direct and indirect costs generated by asthma patients who sought medical care for asthma control over a one-year period in a northern area of Spain were determined. Data were obtained from the patients themselves and severity of illness was classified into mild, moderate and severe according to the International Consensus Report on Diagnosis and Treatment of Asthma, 1992. The average total annual asthma-derived cost was estimated at US$2,879 per patient, with averages of US$1,336 in mildly asthmatic patients, US$2,407 in moderate asthma and US$6,393 in severe asthma. At all levels of severity, indirect costs were twice as high as direct costs, and at the same degree of severity, direct costs due to medication and hospitalization were higher among females than males. A minority of severe asthmatics incurred some 41% of the total costs. The cost of asthma was surprisingly high and varied substantially depending on the degree of severity of the disease. Further knowledge of the costs of asthma across various levels of severity will contribute to a better characterization of optimal intervention strategies for asthma care.

This article has been cited by other articles:

				M Bracken, L Fleming, P Hall, N Van Stiphout, C Bossley, E Biggart, N M Wilson, and A Bush The importance of nurse-led home visits in the assessment of children with problematic asthma Arch. Dis. Child., October 1, 2009; 94(10): 780 - 784. [Abstract] [Full Text] [PDF]

				S. E. Wenzel, P. J. Barnes, E. R. Bleecker, J. Bousquet, W. Busse, S.-E. Dahlen, S. T. Holgate, D. A. Meyers, K. F. Rabe, A. Antczak, et al. A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-{alpha} Blockade in Severe Persistent Asthma Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 549 - 558. [Abstract] [Full Text] [PDF]

				F. Khan, T. S. Hallstrand, M. N. Geddes, W. R. Henderson Jr, and J. Storek Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? Blood, January 8, 2009; 113(2): 279 - 290. [Abstract] [Full Text] [PDF]

				J. Bousquet, U. Wahn, E. O. Meltzer, H. Fox, S. Hedgecock, K. Thomas, and A. Fowler-Taylor Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases Eur. Respir. Rev., April 1, 2008; 17(107): 1 - 9. [Abstract] [Full Text] [PDF]

				J. Shannon, P. Ernst, Y. Yamauchi, R. Olivenstein, C. Lemiere, S. Foley, L. Cicora, M. Ludwig, Q. Hamid, and J. G. Martin Differences in Airway Cytokine Profile in Severe Asthma Compared to Moderate Asthma* Chest, February 1, 2008; 133(2): 420 - 426. [Abstract] [Full Text] [PDF]

				B. H. Rowe and D. Vethanayagam The role of inhaled corticosteroids in the management of acute asthma Eur. Respir. J., December 1, 2007; 30(6): 1035 - 1037. [Full Text] [PDF]

				M. K. Miller, J. H. Lee, P. D. Blanc, D. J. Pasta, S. Gujrathi, H. Barron, S. E. Wenzel, S. T. Weiss, and for the TENOR Study Group TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma Eur. Respir. J., December 1, 2006; 28(6): 1145 - 1155. [Abstract] [Full Text] [PDF]

				M. A. Berry, B. Hargadon, M. Shelley, D. Parker, D. E. Shaw, R. H. Green, P. Bradding, C. E. Brightling, A. J. Wardlaw, and I. D. Pavord Evidence of a Role of Tumor Necrosis Factor {alpha} in Refractory Asthma N. Engl. J. Med., February 16, 2006; 354(7): 697 - 708. [Abstract] [Full Text] [PDF]

				S. C. Erzurum Inhibition of Tumor Necrosis Factor {alpha} for Refractory Asthma N. Engl. J. Med., February 16, 2006; 354(7): 754 - 758. [Full Text] [PDF]

				K. R. Chapman, D. M. Mannino, J. B. Soriano, P. A. Vermeire, A. S. Buist, M. J. Thun, C. Connell, A. Jemal, T. A. Lee, M. Miravitlles, et al. Epidemiology and costs of chronic obstructive pulmonary disease Eur. Respir. J., January 1, 2006; 27(1): 188 - 207. [Full Text] [PDF]

				B. D. Levy, C. Bonnans, E. S. Silverman, L. J. Palmer, G. Marigowda, E. Israel, and for the Severe Asthma Research Program, National H Diminished Lipoxin Biosynthesis in Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 824 - 830. [Abstract] [Full Text] [PDF]

				A V Kamath, I D Pavord, P R Ruparelia, and E R Chilvers Is the neutrophil the key effector cell in severe asthma? Thorax, July 1, 2005; 60(7): 529 - 530. [Full Text] [PDF]

				M. Gaga Fixed obstruction in severe asthma: not just a matter of time Eur. Respir. J., July 1, 2004; 24(1): 8 - 10. [Full Text] [PDF]

				L. Antonicelli, C. Bucca, M. Neri, F. De Benedetto, P. Sabbatani, F. Bonifazi, H-G. Eichler, Q. Zhang, and D.D. Yin Asthma severity and medical resource utilisation Eur. Respir. J., May 1, 2004; 23(5): 723 - 729. [Abstract] [Full Text] [PDF]

				The ENFUMOSA Study Group The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Eur. Respir. J., September 1, 2003; 22(3): 470 - 477. [Abstract] [Full Text] [PDF]

				M. Miravitlles, C. Murio, T. Guerrero, and R. Gisbert Costs of Chronic Bronchitis and COPD: A 1-Year Follow-up Study Chest, March 1, 2003; 123(3): 784 - 791. [Abstract] [Full Text] [PDF]

				N C Thomson and M Shepherd Leukotriene receptor antagonists as add-on therapy for adults with asthma Thorax, March 1, 2003; 58(3): 190 - 192. [Abstract] [Full Text] [PDF]

				B. Schramm, B. Ehlken, A. Smala, K. Quednau, K. Berger, and D. Nowak Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study Eur. Respir. J., January 1, 2003; 21(1): 116 - 122. [Abstract] [Full Text] [PDF]

				E. Van Ganse, L. Laforest, G. Pietri, J.P. Boissel, F. Gormand, R. Ben-Joseph, and P. Ernst Persistent asthma: disease control, resource utilisation and direct costs Eur. Respir. J., August 1, 2002; 20(2): 260 - 267. [Abstract] [Full Text] [PDF]

				P. Godard, P. Chanez, L. Siraudin, N. Nicoloyannis, and G. Duru Costs of asthma are correlated with severity: a 1-yr prospective study Eur. Respir. J., January 1, 2001; 19(1): 61 - 67. [Abstract] [Full Text] [PDF]

				S. Wenzel Proceedings of the ATS Workshop on Refractory Asthma . Current Understanding, Recommendations, and Unanswered Questions Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2341 - 2351. [Full Text]